Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07493824 für Persistent HR-HPV Infection of the Cervix ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection Phase 4 115
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07493824 untersucht Behandlung im Zusammenhang mit Persistent HR-HPV Infection of the Cervix. Diese interventionsstudie der Phase 4 hat den Status offene rekrutierung und startete am 24. Juli 2025. Es ist geplant, 115 Teilnehmer aufzunehmen. Durchgeführt von The First Hospital of Jilin University wird der Abschluss für 31. Mai 2028 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 25. März 2026 aktualisiert.
Kurzbeschreibung
The effectiveness of Patellin ® antibacterial solution in treating persistent cervical HR-HPV infection
Ausführliche Beschreibung
This study is a single-arm, single-center clinical study ® The study was designed to determine the safety of Patelin antibacterial solution in patients with persistent cervical HR-HPV infection availability. The study primarily aims to evaluate the seroconversion rate of cervical HR-HPV in persistent HR-HPV carriers; simultaneously, it compares the positivity rates and copy levels of HPV E6/E7mRNA, changes in gynecol...Mehr anzeigen
Offizieller Titel
Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection
Erkrankungen
Persistent HR-HPV Infection of the CervixWeitere Studien-IDs
- 25K186-001
NCT-Nummer
Studienbeginn (tatsächlich)
2025-07-24
Zuletzt aktualisiert
2026-03-25
Studienende (vorauss.)
2028-05-31
Geplante Rekrutierung
115
Studientyp
Interventionsstudie
PHASE
Phase 4
Status
Offene Rekrutierung
Stichwörter
Patling ® Antibacterial Liquid
Treatment for persistent HPV infection
Treatment for persistent HPV infection
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellSingle-arm, prospective study of the efficacy and safety of Paiteling®Antibacterial Liquid in the tr | Patling ® Antibacterial Liquid Apply Patling ® antibacterial solution locally to the cervix |
Hauptergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
The effectiveness of Patellin ® antibacterial solution in treating persistent cervical HR-HPV infection | Cervical HR-HPV persistent infection HR-HPV seroconversion rate:
5 The rate of turning negative: refers to the reexamination of patients' HR-HPV at a specified time after the end of treatment. Turning negative is defined as the reversal of HR-HPV from persistently positive at enrollment to negative, including all HR-HPV being negative and the reversal of persistently positive HR-HPV to negative while other subtypes are positive. The HR-HPV of the subjects was reviewed 12 months after treatment, and the seroconversion rate of the subtypes of HR-HPV infection that persisted at the time of enrollment was observed and recorded, defined as the seroconversion at that time point. | 24 months |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
26 Years
Zugelassene Geschlechter
Weiblich
- 1 、 Age 25 to 65 years (inclusive), persistent cervical HR-HPV infection (HR-HPV persistent infection refers to infection with the same high-risk HPV subtypes for ≥2 years (this can be from different testing companies; for multiple infections, only one subtyping of HPV persistence is required)); if the cervical biopsy shows chronic cervicitis or low-grade cervical intraepithelial neoplasia; 2. Sexual history; 3. No relevant anti-HPV virus treatment (vaginal or systemic) in the 3 months prior to visit; 4. No pregnancy plan within 6 months of visit 5、 Voluntary signing of informed consent.
- 1、 Cervical biopsy results of TCT or HSIL; 2 、 Cervical HR-HPV infection subtypes changed or reversed to negative; 3. Pregnant or lactating women; 4. Acute inflammation of the genital tract; 5Recent immunodeficiency (chemoradiotherapy, AIDS, SLE); 6. Patients with severe diseases such as diabetes, cardiovascular disease, brain, liver, kidney and hematopoietic system, and mental illness; 7. Those with a history of drug allergy and allergic constitution; 8 Patients who have participated in other clinical trials in the last three months; 9. Suspected or confirmed history of alcohol or drug abuse, or other lesions or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in work environment and unstable living environment that are likely to cause loss of follow-up, according to the investigator's judgment.
The First Hospital of Jilin UniversityVerantwortliche Partei
Songling Zhang, Hauptprüfer, vice president, The First Hospital of Jilin University
Zentrale Studienkontakte
Kontakt: Xiaosen Li Li, +8618343116682, [email protected]
1 Studienstandorte in 1 Ländern
Jilin
The First Hospital of Jilin University, Changchun, Jilin, 130000, China
Zhentong Wei Medic, Kontakt, 15804300686, [email protected]
Offene Rekrutierung